Patient characteristics based on TET2 and DNM3TA mutational status
| Variable . | Overall N (%) . | TET2 . | DNMT3A . | ||||
|---|---|---|---|---|---|---|---|
| Unmutated N (%) . | Mutated N (%) . | P value* . | Unmutated N (%) . | Mutated N (%) . | P value* . | ||
| N | 85 | 20 | 65 | 57 | 28 | ||
| Gender | |||||||
| Female | 41 (48) | 9 (45) | 32 (49) | .80 | 31 (54) | 10 (36) | .11 |
| Male | 43 (51) | 11 (55) | 32 (49) | 25 (44) | 18 (64) | ||
| Unknown | 1 (1) | 0 (0) | 1 (1) | 1 (2) | 0 (0) | ||
| Median age at Dx (range) | 69 (30, 89) | 63 (30, 85) | 72 (48, 89) | .060 | 67 (30, 88) | 73 (58, 89) | .037 |
| Stage | |||||||
| II | 1 (1) | 0 (0) | 1 (1) | >.99 | 1 (2) | 0 (0) | .66 |
| III-IV | 28 (33) | 8 (40) | 20 (31) | 19 (33) | 9 (32) | ||
| IV | 23 (27) | 7 (35) | 16 (25) | 18 (32) | 5 (18) | ||
| Unknown | 33 (39) | 5 (25) | 28 (43) | 19 (33) | 14 (50) | ||
| B-Symptoms | |||||||
| Yes | 33 (39) | 7 (35) | 26 (40) | .20 | 23 (40) | 10 (36) | .74 |
| No | 18 (21) | 7 (35) | 11 (17) | 14 (25) | 4 (14) | ||
| Unknown | 34 (40) | 6 (30) | 28 (43) | 20 (35) | 14 (50) | ||
| Elevated LDH | |||||||
| Yes | 31 (36) | 6 (30) | 25 (38) | .038 | 23 (40) | 8 (29) | >.99 |
| No | 21 (25) | 10 (50) | 11 (17) | 15 (26) | 6 (21) | ||
| Unknown | 33 (39) | 4 (20) | 29 (45) | 19 (33) | 14 (50) | ||
| BM involvement | |||||||
| Yes | 10 (12) | 3 (15) | 7 (11) | .18 | 8 (14) | 2 (7) | .45 |
| No | 26 (31) | 9 (45) | 17 (26) | 19 (33) | 7 (25) | ||
| Unknown | 49 (58) | 8 (40) | 41 (63) | 30 (53) | 19 (68) | ||
| ECOG PS | |||||||
| 0-1 | 22 (26) | 6 (30) | 16 (25) | .47 | 17 (30) | 5 (18) | .49 |
| 2-3 | 19 (22) | 3 (15) | 16 (25) | 12 (21) | 7 (25) | ||
| Unknown | 44 (52) | 11 (55) | 33 (51) | 28 (49) | 16 (57) | ||
| Extranodal disease | |||||||
| Yes | 19 (22) | 5 (25) | 14 (22) | .75 | 16 (28) | 3 (11) | .33 |
| No | 30 (35) | 10 (50) | 20 (31) | 21 (37) | 9 (32) | ||
| Unknown | 36 (42) | 5 (25) | 31 (48) | 20 (35) | 16 (57) | ||
| IPI score | |||||||
| 1-2 | 11 (13) | 4 (20) | 7 (11) | .42 | 10 (18) | 1 (4) | .24 |
| 3-5 | 33 (39) | 7 (35) | 26 (40) | 23 (40) | 10 (36) | ||
| Unknown | 41 (48) | 9 (45) | 32 (49) | 24 (42) | 17 (61) | ||
| PIT score | |||||||
| 0-1 | 11 (13) | 5 (25) | 6 (9) | .12 | 10 (18) | 1 (3) | .23 |
| 2-4 | 31 (36) | 6 (30) | 25 (38) | 21 (37) | 10 (36) | ||
| Unknown | 43 (51) | 9 (45) | 34 (52) | 26 (46) | 17 (61) | ||
| Median OS (mo) | 18 | 18 | 25 | .99 | 25 | 17 | .81 |
| 95% confidence interval | (12,51) | (2, 104) | (12, 31) | (11, 51) | (4, NR) | ||
| Variable . | Overall N (%) . | TET2 . | DNMT3A . | ||||
|---|---|---|---|---|---|---|---|
| Unmutated N (%) . | Mutated N (%) . | P value* . | Unmutated N (%) . | Mutated N (%) . | P value* . | ||
| N | 85 | 20 | 65 | 57 | 28 | ||
| Gender | |||||||
| Female | 41 (48) | 9 (45) | 32 (49) | .80 | 31 (54) | 10 (36) | .11 |
| Male | 43 (51) | 11 (55) | 32 (49) | 25 (44) | 18 (64) | ||
| Unknown | 1 (1) | 0 (0) | 1 (1) | 1 (2) | 0 (0) | ||
| Median age at Dx (range) | 69 (30, 89) | 63 (30, 85) | 72 (48, 89) | .060 | 67 (30, 88) | 73 (58, 89) | .037 |
| Stage | |||||||
| II | 1 (1) | 0 (0) | 1 (1) | >.99 | 1 (2) | 0 (0) | .66 |
| III-IV | 28 (33) | 8 (40) | 20 (31) | 19 (33) | 9 (32) | ||
| IV | 23 (27) | 7 (35) | 16 (25) | 18 (32) | 5 (18) | ||
| Unknown | 33 (39) | 5 (25) | 28 (43) | 19 (33) | 14 (50) | ||
| B-Symptoms | |||||||
| Yes | 33 (39) | 7 (35) | 26 (40) | .20 | 23 (40) | 10 (36) | .74 |
| No | 18 (21) | 7 (35) | 11 (17) | 14 (25) | 4 (14) | ||
| Unknown | 34 (40) | 6 (30) | 28 (43) | 20 (35) | 14 (50) | ||
| Elevated LDH | |||||||
| Yes | 31 (36) | 6 (30) | 25 (38) | .038 | 23 (40) | 8 (29) | >.99 |
| No | 21 (25) | 10 (50) | 11 (17) | 15 (26) | 6 (21) | ||
| Unknown | 33 (39) | 4 (20) | 29 (45) | 19 (33) | 14 (50) | ||
| BM involvement | |||||||
| Yes | 10 (12) | 3 (15) | 7 (11) | .18 | 8 (14) | 2 (7) | .45 |
| No | 26 (31) | 9 (45) | 17 (26) | 19 (33) | 7 (25) | ||
| Unknown | 49 (58) | 8 (40) | 41 (63) | 30 (53) | 19 (68) | ||
| ECOG PS | |||||||
| 0-1 | 22 (26) | 6 (30) | 16 (25) | .47 | 17 (30) | 5 (18) | .49 |
| 2-3 | 19 (22) | 3 (15) | 16 (25) | 12 (21) | 7 (25) | ||
| Unknown | 44 (52) | 11 (55) | 33 (51) | 28 (49) | 16 (57) | ||
| Extranodal disease | |||||||
| Yes | 19 (22) | 5 (25) | 14 (22) | .75 | 16 (28) | 3 (11) | .33 |
| No | 30 (35) | 10 (50) | 20 (31) | 21 (37) | 9 (32) | ||
| Unknown | 36 (42) | 5 (25) | 31 (48) | 20 (35) | 16 (57) | ||
| IPI score | |||||||
| 1-2 | 11 (13) | 4 (20) | 7 (11) | .42 | 10 (18) | 1 (4) | .24 |
| 3-5 | 33 (39) | 7 (35) | 26 (40) | 23 (40) | 10 (36) | ||
| Unknown | 41 (48) | 9 (45) | 32 (49) | 24 (42) | 17 (61) | ||
| PIT score | |||||||
| 0-1 | 11 (13) | 5 (25) | 6 (9) | .12 | 10 (18) | 1 (3) | .23 |
| 2-4 | 31 (36) | 6 (30) | 25 (38) | 21 (37) | 10 (36) | ||
| Unknown | 43 (51) | 9 (45) | 34 (52) | 26 (46) | 17 (61) | ||
| Median OS (mo) | 18 | 18 | 25 | .99 | 25 | 17 | .81 |
| 95% confidence interval | (12,51) | (2, 104) | (12, 31) | (11, 51) | (4, NR) | ||
Test includes only known categories. BM, bone marrow; Dx, diagnosis; IPI, International Prognostic Index; NR, not reached; PIT, Prognostic Index for T-cell lymphoma; PS, performance status.